These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 10786665

  • 1. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.
    Zheng FF, Kuduk SD, Chiosis G, Münster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N.
    Cancer Res; 2000 Apr 15; 60(8):2090-4. PubMed ID: 10786665
    [Abstract] [Full Text] [Related]

  • 2. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
    Münster PN, Marchion DC, Basso AD, Rosen N.
    Cancer Res; 2002 Jun 01; 62(11):3132-7. PubMed ID: 12036925
    [Abstract] [Full Text] [Related]

  • 3. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH.
    Mol Cancer Res; 2009 Feb 01; 7(2):275-84. PubMed ID: 19208749
    [Abstract] [Full Text] [Related]

  • 4. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
    Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L.
    Clin Cancer Res; 2001 Jul 01; 7(7):2076-84. PubMed ID: 11448926
    [Abstract] [Full Text] [Related]

  • 5. Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.
    Ochel HJ, Eichhorn K, Gademann G.
    Cell Stress Chaperones; 2001 Apr 01; 6(2):105-12. PubMed ID: 11599571
    [No Abstract] [Full Text] [Related]

  • 6. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells.
    Wang K, Ma Q, Ren Y, He J, Zhang Y, Zhang Y, Chen W.
    Oncol Rep; 2007 Jan 01; 17(1):89-96. PubMed ID: 17143483
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.
    Münster PN, Srethapakdi M, Moasser MM, Rosen N.
    Cancer Res; 2001 Apr 01; 61(7):2945-52. PubMed ID: 11306472
    [Abstract] [Full Text] [Related]

  • 8. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
    Schulte TW, Neckers LM.
    Cancer Chemother Pharmacol; 1998 Apr 01; 42(4):273-9. PubMed ID: 9744771
    [Abstract] [Full Text] [Related]

  • 9. The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines.
    Park JW, Yeh MW, Wong MG, Lobo M, Hyun WC, Duh QY, Clark OH.
    J Clin Endocrinol Metab; 2003 Jul 01; 88(7):3346-53. PubMed ID: 12843186
    [Abstract] [Full Text] [Related]

  • 10. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.
    Basso AD, Solit DB, Munster PN, Rosen N.
    Oncogene; 2002 Feb 14; 21(8):1159-66. PubMed ID: 11850835
    [Abstract] [Full Text] [Related]

  • 11. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 12. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L.
    Clin Cancer Res; 2003 Oct 15; 9(13):4961-71. PubMed ID: 14581371
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY, Kamal A, Busch D, Thao L, Zhang L, Timony G, Grecko R, Trent K, Lough R, Salazar T, Khan S, Burrows F, Boehm MF.
    J Med Chem; 2004 Jul 15; 47(15):3865-73. PubMed ID: 15239664
    [Abstract] [Full Text] [Related]

  • 14. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
    Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros A, Dunach M, Neckers LM.
    Cancer Res; 2001 Feb 15; 61(4):1671-7. PubMed ID: 11245482
    [Abstract] [Full Text] [Related]

  • 15. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D.
    Cancer Res; 2003 Dec 15; 63(24):8984-95. PubMed ID: 14695217
    [Abstract] [Full Text] [Related]

  • 16. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.
    Nimmanapalli R, O'Bryan E, Bhalla K.
    Cancer Res; 2001 Mar 01; 61(5):1799-804. PubMed ID: 11280726
    [Abstract] [Full Text] [Related]

  • 17. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
    Wong TW, Lee FY, Yu C, Luo FR, Oppenheimer S, Zhang H, Smykla RA, Mastalerz H, Fink BE, Hunt JT, Gavai AV, Vite GD.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6186-93. PubMed ID: 17062696
    [Abstract] [Full Text] [Related]

  • 18. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation.
    Tikhomirov O, Carpenter G.
    Cancer Res; 2003 Jan 01; 63(1):39-43. PubMed ID: 12517775
    [Abstract] [Full Text] [Related]

  • 19. Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells.
    Nishiyama N, Nori A, Malugin A, Kasuya Y, Kopecková P, Kopecek J.
    Cancer Res; 2003 Nov 15; 63(22):7876-82. PubMed ID: 14633716
    [Abstract] [Full Text] [Related]

  • 20. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity.
    An WG, Schnur RC, Neckers L, Blagosklonny MV.
    Cancer Chemother Pharmacol; 1997 Nov 15; 40(1):60-4. PubMed ID: 9137531
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.